PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33772987-13	2021	Based on these results, IV tPA should be offered as a treatment for WUS patients with favorable neuroimaging findings.	Tetradecanoylphorbol Acetate	27-30	DnaJ heat shock protein family (Hsp40) member C22	Homo sapiens	68-71	
33724081-11	2022	INTERPRETATION: Our single-center analysis and meta-analysis suggest that tPA can be safely administered based on NCCT with comparable rates of sICH for select WUS/UNK stroke patients.	Tetradecanoylphorbol Acetate	74-77	DnaJ heat shock protein family (Hsp40) member C22	Homo sapiens	160-163	
33772987-3	2021	We performed a systematic review and meta-analysis of the efficacy and safety of IV tPA compared with normal saline, placebo, or no treatment in patients with WUS using imaging-based treatment algorithms.	Tetradecanoylphorbol Acetate	84-87	DnaJ heat shock protein family (Hsp40) member C22	Homo sapiens	159-162	
33772987-5	2021	We included controlled trials (randomized or nonrandomized), observational cohort studies (prospective or retrospective), and single-arm studies in which adults with WUS were administered IV tPA after MR- or CT-based imaging.	Tetradecanoylphorbol Acetate	191-194	DnaJ heat shock protein family (Hsp40) member C22	Homo sapiens	166-169